These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 31912664)

  • 41. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
    Shah PD; Patil S; Dickler MN; Offit K; Hudis CA; Robson ME
    Cancer; 2016 Apr; 122(8):1178-84. PubMed ID: 26859126
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of Outcomes Between BRCA Pathogenic Variant Carriers Undergoing Breast-Conserving Surgery Versus Mastectomy.
    Shubeck S; Sevilimedu V; Berger E; Robson M; Heerdt AS; Pilewskie ML
    Ann Surg Oncol; 2022 Aug; 29(8):4706-4713. PubMed ID: 35585432
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes.
    Welsh JL; Hoskin TL; Day CN; Thomas AS; Cogswell JA; Couch FJ; Boughey JC
    Ann Surg Oncol; 2017 Oct; 24(10):3067-3072. PubMed ID: 28766224
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Newly diagnosed breast cancer patients choose bilateral mastectomy over breast-conserving surgery when testing positive for a BRCA1/2 mutation.
    Stolier AJ; Corsetti RL
    Am Surg; 2005 Dec; 71(12):1031-3. PubMed ID: 16447474
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The spectrum of BRCA1 and BRCA2 mutations and clinicopathological characteristics in Chinese women with early-onset breast cancer.
    Chen L; Fu F; Huang M; Lv J; Zhang W; Wang C
    Breast Cancer Res Treat; 2020 Apr; 180(3):759-766. PubMed ID: 32072338
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer.
    Narod SA
    Breast Cancer Res Treat; 2011 Jul; 128(2):581-3. PubMed ID: 21455666
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis.
    Valachis A; Nearchou AD; Lind P
    Breast Cancer Res Treat; 2014 Apr; 144(3):443-55. PubMed ID: 24567198
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
    Zhong Q; Peng HL; Zhao X; Zhang L; Hwang WT
    Clin Cancer Res; 2015 Jan; 21(1):211-20. PubMed ID: 25348513
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prediction and clinical utility of a contralateral breast cancer risk model.
    Giardiello D; Steyerberg EW; Hauptmann M; Adank MA; Akdeniz D; Blomqvist C; Bojesen SE; Bolla MK; Brinkhuis M; Chang-Claude J; Czene K; Devilee P; Dunning AM; Easton DF; Eccles DM; Fasching PA; Figueroa J; Flyger H; García-Closas M; Haeberle L; Haiman CA; Hall P; Hamann U; Hopper JL; Jager A; Jakubowska A; Jung A; Keeman R; Kramer I; Lambrechts D; Le Marchand L; Lindblom A; Lubiński J; Manoochehri M; Mariani L; Nevanlinna H; Oldenburg HSA; Pelders S; Pharoah PDP; Shah M; Siesling S; Smit VTHBM; Southey MC; Tapper WJ; Tollenaar RAEM; van den Broek AJ; van Deurzen CHM; van Leeuwen FE; van Ongeval C; Van't Veer LJ; Wang Q; Wendt C; Westenend PJ; Hooning MJ; Schmidt MK
    Breast Cancer Res; 2019 Dec; 21(1):144. PubMed ID: 31847907
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing.
    Elsayegh N; Kuerer HM; Lin H; Gutierrez Barrera AM; Jackson M; Muse KI; Litton JK; Albarracin C; Afrough A; Hortobagyi GN; Arun BK
    Ann Surg Oncol; 2014 Oct; 21(11):3466-72. PubMed ID: 24796968
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series.
    Robson M; Svahn T; McCormick B; Borgen P; Hudis CA; Norton L; Offit K
    Cancer; 2005 Jan; 103(1):44-51. PubMed ID: 15558796
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
    Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
    Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients.
    Zhong X; Dong Z; Dong H; Li J; Peng Z; Deng L; Zhu X; Sun Y; Lu X; Shen F; Su X; Zhang L; Gu Y; Zheng H
    PLoS One; 2016; 11(6):e0156789. PubMed ID: 27257965
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy.
    Pierce LJ; Phillips KA; Griffith KA; Buys S; Gaffney DK; Moran MS; Haffty BG; Ben-David M; Kaufman B; Garber JE; Merajver SD; Balmaña J; Meirovitz A; Domchek SM
    Breast Cancer Res Treat; 2010 Jun; 121(2):389-98. PubMed ID: 20411323
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of breast surgical procedure on survival in BRCA mutated patients with invasive breast cancer: Mastectomy versus conservative treatment.
    Mahiou K; Jankowski C; Vincent L; Costaz H; Padeano MM; Mamguem A; Dabakuyo S; Coutant C
    J Gynecol Obstet Hum Reprod; 2024 May; 53(5):102760. PubMed ID: 38428460
    [TBL] [Abstract][Full Text] [Related]  

  • 56. What made her give up her breasts: a qualitative study on decisional considerations for contralateral prophylactic mastectomy among breast cancer survivors undergoing BRCA1/2 genetic testing.
    Kwong A; Chu AT
    Asian Pac J Cancer Prev; 2012; 13(5):2241-7. PubMed ID: 22901201
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.
    Robson ME; Chappuis PO; Satagopan J; Wong N; Boyd J; Goffin JR; Hudis C; Roberge D; Norton L; Bégin LR; Offit K; Foulkes WD
    Breast Cancer Res; 2004; 6(1):R8-R17. PubMed ID: 14680495
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study.
    Akdeniz D; van Barele M; Heemskerk-Gerritsen BAM; Steyerberg EW; Hauptmann M; ; van de Beek I; van Engelen K; Wevers MR; Gómez García EB; Ausems MGEM; Berger LPV; van Asperen CJ; Adank MA; Collée MJ; Stommel-Jenner DJ; Jager A; Schmidt MK; Hooning MJ
    Breast; 2022 Feb; 61():98-107. PubMed ID: 34929424
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriers.
    McCrorie AD; Ashfield S; Begley A; Mcilmunn C; Morrison PJ; Boyd C; Eccles B; Greville-Heygate S; Copson ER; Cutress RI; Eccles DM; Savage KI; McIntosh SA
    J Pathol Clin Res; 2020 Apr; 6(2):146-153. PubMed ID: 32022473
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis.
    Basu NN; Ingham S; Hodson J; Lalloo F; Bulman M; Howell A; Evans DG
    Fam Cancer; 2015 Dec; 14(4):531-8. PubMed ID: 26239694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.